and received consultancy/speaker fees from AC Immune, ALZpath, Amylyx, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche, and Siemens
Clinical studies show significant reductions in cardiovascular risk, with some medications reducing major adverse cardiovascular events by up to 20%
Patients seeking BPC-157 in the Jacksonville and Ponte Vedra area should understand they are entering investigational territory
Receptors can be deleted in specific tissues with Cre-Lox or knocked down by local administration of antisense RNA such as in specific brain nuclei (19)